Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019

Jessica Leung; Scott D Grosse; Kai Hong; Megan H Pesch; Tatiana M Lanzieri

doi:10.1016/j.jpeds.2022.03.042

Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019

J Pediatr. 2022 Jul:246:274-278.e2. doi: 10.1016/j.jpeds.2022.03.042. Epub 2022 Mar 28.

Authors

Jessica Leung¹, Scott D Grosse², Kai Hong³, Megan H Pesch⁴, Tatiana M Lanzieri³

Affiliations

¹ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Electronic address: JLeung@cdc.gov.
² National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA.
³ National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA.
⁴ Division of Developmental and Behavioral Pediatrics, Department of Pediatrics, University of Michigan, Ann Arbor, MI.

PMID: 35358586
DOI: 10.1016/j.jpeds.2022.03.042

Abstract

From 2009-2015 to 2016-2019, the proportion of infants in the US with congenital cytomegalovirus treated with valganciclovir roughly doubled for infants enrolled with employer-sponsored insurance (from 16% to 29%) and Medicaid (from 16% to 36%). The proportion treated with valganciclovir increased for all congenital cytomegalovirus disease severity groups.

Keywords: CMV; administrative data; antiviral; congenital cytomegalovirus; valganciclovir.

Published by Elsevier Inc.

Publication types

Case Reports

MeSH terms

Antiviral Agents / therapeutic use
Cytomegalovirus Infections* / diagnosis
Cytomegalovirus Infections* / drug therapy
Cytomegalovirus*
Humans
Infant
Medicaid
United States
Valganciclovir / therapeutic use

Substances

Antiviral Agents
Valganciclovir